Skip to main content
Premium Trial:

Request an Annual Quote

David Ebsworth, James Niedel, Daniel Chelsky


Oxford Glycosciences has named David Ebsworth CEO effective July 1, 2002, the company said last week. Ebsworth will replace Michael Kranda, who is leaving the company for family reasons, the company said in March. Ebsworth most recently served as head of the worldwide pharmaceutical business group of Bayer. Prior to that, he was president of Bayer’s North American pharmaceutical division, with responsibility for all functions from research through clinical development, regulatory affairs, sales and marketing, and finance and strategy.

Venture-capital firm Sprout Group has hired former GlaxoSmithKline chief science and technology officer James Niedel, the company said last week. Niedel will be venture partner for health-care technology investments. Between 1995 and 2001, Niedel was a board member at Glaxo Wellcome, where he oversaw global R&D, information technology, and product strategy. The Sprout Group is a venture capital affiliate of Credit Suisse First Boston.

Daniel Chelsky will join Caprion Pharmaceuticals as executive vice president and chief scientific officer, the company said last week. Chelsky replaces John Bergeron as CSO, a McGill University professor and co-founder of the company who will remain affiliated with Caprion as a member of its scientific advisory board. Chelsky most recently served as president and general manager of BioSignal Packard, a division of PerkinElmer, where he oversaw the development of technology development for drug discovery and genomics research. He has also worked at Pharmacopeia, where he served as senior director of biology.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.